The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & Johnson because of its lack of effectiveness in the target patient population.
No new safety signals were found, and the results verified that aticaprant is safe and well-tolerated. Based on this mechanism’s potential, the company will investigate aticaprant’s future development prospects in other high-unmet-need domains.
Comprehensive evaluations from the VENTURA development program are under progress and will be presented at a subsequent medical conference.
Source: Johnson & Johnson
